The FDA recognised the risk for myocarditis and pericarditis from the COVID-19 mRNA vaccines was real, especially in younger males after the second dose, but judged it to still be rare, and cited a VAERS-derived figure of 6.5 per 100,000 and up to 20 per 100,000 for adolescent boys. The FDA did not calculate that [such] databases ... have a large under-reporting factor.

A common factor in this ... estimate ... is the [FDA's] failure to mention the perennial problem of underreporting in passive notification systems. ... Compounding the phenomenon of underreporting in the case of myocarditis, is that this diagnosis is difficult to make, and often depends on the availability of specialty units, cardiac MRI facilities and/or endomyocardial biopsy (EMB). The diagnosis can mimic myocardial infarction and thus can be misdiagnosed. In this regard, the paper by Baumeier ... noted that a third of those with histologically confirmed myocarditis, categorised as vaccine-associated on the basis of history and exclusion of other causative agents, did not have cardiac MRI evidence of myocarditis. Further, many cases of myocarditis are subclinical and may be missed in the acute phase.

Although the public health authorities’ narrative is that myocarditis from COVID-19 vaccines is mild and self-limiting, the evidence is that ... pathological changes in these young hearts are persistent. An Italian study followed 13 cases of post mRNA vaccine-induced myopericarditis, myocarditis or pericarditis, median age 15 years, for 12 weeks. Although overt symptoms in all but one case resolved, 12 of the 13 adolescents still had ... signs of “persistent ... myocardial injury” at the study end.

The authors describe the mechanisms by which these clotting effects are more common in younger patients.

These mechanisms would explain clotting to both the virus and the spike proteins produced by the gene-based COVID-19 vaccines. It also suggests that public health policies that negated natural immunity and mandated COVID-19 vaccination, and booster programs, put the young and non-elderly population at greater risk.

Myopericarditis is recognised but often has been downplayed as mild and rare, yet the evidence for relatively common subclinical COVID-19 vaccine-related myopericarditis and autopsy evidence suggests a role in sudden deaths in relatively young and fit people.

The FDA recognised the risk for myocarditis and pericarditis from the COVID-19 mRNA vaccines was real, especially in younger males after the second dose, but judged it to still be rare, and cited a VAERS-derived figure of 6.5 per 100,000 and up to 20 per 100,000 for adolescent boys. The FDA did not calculate that [such] databases ... have a large under-reporting factor.

A common factor in this ... estimate ... is the [FDA's] failure to mention the perennial problem of underreporting in passive notification systems. ... Compounding the phenomenon of underreporting in the case of myocarditis, is that this diagnosis is difficult to make, and often depends on the availability of specialty units, cardiac MRI facilities and/or endomyocardial biopsy (EMB). The diagnosis can mimic myocardial infarction and thus can be misdiagnosed. In this regard, the paper by Baumeier ... noted that a third of those with histologically confirmed myocarditis, categorised as vaccine-associated on the basis of history and exclusion of other causative agents, did not have cardiac MRI evidence of myocarditis. Further, many cases of myocarditis are subclinical and may be missed in the acute phase.

Although the public health authorities’ narrative is that myocarditis from COVID-19 vaccines is mild and self-limiting, the evidence is that ... pathological changes in these young hearts are persistent. An Italian study followed 13 cases of post mRNA vaccine-induced myopericarditis, myocarditis or pericarditis, median age 15 years, for 12 weeks. Although overt symptoms in all but one case resolved, 12 of the 13 adolescents still had ... signs of “persistent ... myocardial injury” at the study end.

The authors describe the mechanisms by which these clotting effects are more common in younger patients.

These mechanisms would explain clotting to both the virus and the spike proteins produced by the gene-based COVID-19 vaccines. It also suggests that public health policies that negated natural immunity and mandated COVID-19 vaccination, and booster programs, put the young and non-elderly population at greater risk.

Myopericarditis is recognised but often has been downplayed as mild and rare, yet the evidence for relatively common subclinical COVID-19 vaccine-related myopericarditis and autopsy evidence suggests a role in sudden deaths in relatively young and fit people.